Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience

Lung Cancer

Volumn 55, Issue 3, 2007, Pages 357-363

  Gauthier, I ^a   Ding, K ^a   Winton, T ^a   Shepherd, F A ^a   Livingston, R ^b   Johnson, D H ^c   Rigas, J R ^d   Whitehead, M ^a   Graham, B ^a   Seymour, L ^a  

^a Clinical Trials Group   (Canada)

^b Southwest Oncology Group   (United States)

^c Eastern Cooperative Oncology Group   (United States)

^d Cancer and Leukemia Group B   (United States)

Author keywords

Adjuvant chemotherapy; Clinical outcomes; Hb levels; NSCLC

Indexed keywords

CISPLATIN; HEMOGLOBIN; NAVELBINE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 33847283017     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.10.021     Document Type: Article

References (34)

1. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 25 (2005) 2640-2642
2. Douillard J., Rosell R., Delena M., Legroumellec A., Torres A., and Carpagnano F. ANITA: phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (satge I-III) non-small-cell lung cancer (NSCLC) patients: final results after 70-month median follow-up on behalf of the Adjuvant Navelbine International Trialist Association. Proc Am Soc Clin Oncol (2005) [abstract 7013]
3. Strauss G.M., Herndon J., Maddaus M.A., Johnstone D.W., Johnson E.A., Watson D.M., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol (2004) [abstract 7019]
4. Strauss G.M., Herndon J.E., Maddaus M.A., Johnston D.W., Johnson E.A., Watson D.M., et al. Adjuvant chemotherapy in stage IB non-small-cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol (2006) [abstract 7007]
5. 2) plus carboplatin in non-small-cell lung cancer: a randomized study. Semin Oncol 24 Suppl. 12 (1997) S12-30-S12-33
6. Pirker R., Krajnok G., Zochbauer S., Malayeri R., Kneussl M., Huber H., et al. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 6 (1995) 833-835
7. Von Pawel J., Wagner H., Niederle N., Heider A., Koschel G., Gromotka E., et al. Paclitaxel and cisplatin in patients with non-small cell lung cancer: results of a phase II trial. Semin Oncol 23 (1996) 7-9
8. Postmus P.E., Giaccone G., Debruyne C., Sahmoud T., Splinter T.A., and van Zandwijk N. Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group. Semin Oncol 23 Suppl. 12 (1996) 10-13
9. Abratt R.P., Hacking D.J., Goedhals L., and Bezdowa W.R. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24 Suppl. 8 (1997) S8-18-S8-23
10. Shepherd F.A., Cormier Y., Burkes R., Evans W.K., Goss G., Klimo P., et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24 Suppl. 8 (1997) S-27-S8-30
11. Lippe P., Tummarello D., Monterubbianesi M.C., Sylva R.R., Giuliodori L., Mari D., et al. Weekly gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase II study. Ann Oncol 10 2 (1999) 217-221
12. Mok T.S., Lam K.C., Lee C., Zhang L., Wong H., Chan A.T., et al. Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Oncology 68 4-6 (2005) 485-492
13. Wozniak A.J., Crowley J.J., Balcerzak S.P., Weiss G.R., Spiridonidis C.H., Baker L.H., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 16 (1998) 2459-2465
14. Perng R.P., Shih J.F., Chen Y.M., Delgado F.M., Tsai C.M., Chou K.C., et al. A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small-cell lung cancer. Am J Clin Oncol 23 1 (2000) 60-64
15. Horvath L., Boyer M., Clarke S., Beale P., Beith J., Underhill C., et al. Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer. Lung Cancer 32 2 (2001) 173-178
16. Georgoulias V., Ardavanis A., Tsiafaki X., Agelidou A., Mixalopoulou P., Anagnostopoulou O., et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23 13 (2005) 2937-2945
17. Okamoto H., Saijo N., Shinkai T., Eguchi K., Sasaki Y., Tamura T., et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann Oncol 3 10 (1992) 819-824
18. Albain K.S., Crowley J.J., LeBlanc M., and Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9 (1991) 1618-1626
19. Caro J.J., Salas M., Ward A., and Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91 12 (2001) 2214-2221
20. Morere J.F. Role of epoetin in the management of anemia in patients with lung cancer. Lung Cancer 46 2 (2004) 149-156
21. Van Acht M.J., Hermans J., Boks D.E., and Leer J.W. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laringuela carcinoma. Radiother Oncol 23 (1992) 229-235
22. Grogan M., Thomas G.M., Melamed I., Wong F.L., Pearcy R.G., Jospeh P.K., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
23. Waters J.S., O'Brien M.E., and Ashley S. Management of anemia in patients receiving chemotherapy. J Clin Oncol 20 (2002) 601-603
24. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362 9392 (2003) 1255-1260
25. Leyland-Jones B., and BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4 8 (2003) 459-460
26. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 25 (2005) 5960-5972
27. Goss G., Feld R., Bezjak A., Perry G., Melosky B., Smith C., et al. Impact of maintaining hemoglobin with epoetin alfa on time to progression, overall survival, quality of life, and transfusion reduction in limited disease small cell lung cancer patients. Lung Cancer 49 Suppl. 2 (2005) S53 [2005 (abstract)]
28. Bohlius J., Langensiepen S., Schwarzer G., Seidenfeld J., Piper M., Bennett C., et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97 7 (2005) 489-498
29. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D., et al. Use of epoetin with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20 19 (2002) 4083-4107
30. The NCCN Anemia Panel. NCCN clinical practice guideline in oncology: cancer and treatment-related anemia, version 1; 2005. Available on line at http://www.nccn.org/physician_gls/f_guidelines.html (23 March 2005, date last accessed).
31. Di Maio M., Gridelli C., Gallo C., Shepherd F., Piantedosi F.V., Cigolari S., et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer; a pooled analysis of three randomized trials. Lancet Oncol 6 9 (2005) 637-638
32. Laurie S., Ding K., Whitehead M., Feld R., Murray N., Seymour L., et al. Impact of anemia on outcomes of therapy in limited small cell lung cancer: an analysis of studies performed by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Lung Cancer 49 Suppl. 2 (2005) S323 [abstract]
33. Nosotti M., Rebulla P., Riccardi D., Baisi A., Bellaviti N., Rosso L., et al. Correlation between perioperative blood transfusión and prognosos of patients subjected to surgery for stage I lung cancer. Chest 124 (2003) 102-107
34. Berardi R., Brunelli A., Tamburrano T., Verdecchia L., Onofri A., Zuccatosta L., et al. Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for NSCLC. Lung Cancer 49 (2005) 371-376